Research programme: anti-viral therapeutics - Globavir

Drug Profile

Research programme: anti-viral therapeutics - Globavir

Alternative Names: GBV 001; GBV-012; GBV-015

Latest Information Update: 26 Aug 2014

Price : $50

At a glance

  • Originator Stanford University School of Medicine
  • Developer Globavir Biosciences
  • Class
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue; Ebola virus infections; Hepatitis B; Human papillomavirus infections; West Nile virus infections
  • Research Chikungunya virus infections; Hantavirus infections; Lassa fever; Marburg virus disease

Most Recent Events

  • 18 Aug 2014 Early research in Lassa fever in USA (unspecified route)
  • 18 Aug 2014 Early research in Hantavirus infections in USA (unspecified route)
  • 18 Aug 2014 Early research in Marburg virus disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top